Advice
in the absence of a submission from the holder of the marketing authorisation
interferon beta-1a (Rebif®) is not recommended for use within NHS Scotland.
Indication under review: patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- interferon beta-1a (Rebif)
- SMC ID:
- 825/12
- Indication:
- Patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 November 2012